Drug intelligence / Profile preview

BB-OTC

Development stage: Preclinical
Lead developer: Enlivex Therapeutics
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

BB-OTC is a drug candidate being developed by BioBlast Pharma for the treatment of Ornithine Transcarbamylase Deficiency. It utilizes BioBlast's mitochondrial protein replacement platform (mPRT), which was licensed from Yissum, the technology transfer company of the Hebrew University of Jerusalem. The platform is designed to replace mitochondrial proteins. The licensing agreement includes tiered low single-digit royalties on net sales and a percentage of sublicensing fees.

Targets

OCT (Organic cation transporter family)

Beyond the preview

Go deeper on BB-OTC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-OTC.

Explore the full profile